R
Randall P. Rago
Researcher at University of Wisconsin-Madison
Publications - 7
Citations - 435
Randall P. Rago is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Suramin & Cumulative dose. The author has an hindex of 6, co-authored 7 publications receiving 428 citations. Previous affiliations of Randall P. Rago include University of Tennessee Health Science Center.
Papers
More filters
Journal ArticleDOI
Prooxidant-Antioxidant Shift Induced by Androgen Treatment of Human Prostate Carcinoma Cells
TL;DR: Physiologic levels of androgens are capable of increasing oxidative stress in androgen-responsive LNCaP prostate carcinoma cells, and the evidence suggests that this result is due in part to increased mitochondrial activity.
Journal ArticleDOI
Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.
Jordan Berlin,Kendra D. Tutsch,Paul R. Hutson,James M. Cleary,Randall P. Rago,Rhoda Z. Arzoomanian,D. Alberti,C. Feierabend,George Wilding +8 more
TL;DR: The maximum-tolerated dose (MTD) for the gelcap formulation was 75 mg/m2 with dose-limiting neurocerebellar toxicity (ataxia) seen at 100 mg/ m2, with prominent side effects, including nausea, vomiting, and fatigue, were partially alleviated through altering the administration schedule to nighttime dosing.
Journal ArticleDOI
Suramin‐induced weakness from hypophosphatemia and mitochondrial myopathy. Association of suramin with mitochondrial toxicity in humans
TL;DR: Two potential causes of suramin‐induced muscular weakness are described and an antiparasitic drug being evaluated as an antitumor compound is described.
Journal ArticleDOI
Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates.
TL;DR: Primary epithelial cultures derived from normal, benign hyperplastic, and cancerous human prostate tissue were treated with increasing doses of suramin, and assayed for cell proliferation over a period of days, demonstrating no differential response to suramin among the prostate PECs derived from different tissues.
Journal Article
Disruption of mitochondrial function by suramin measured by rhodamine 123 retention and oxygen consumption in intact DU145 prostate carcinoma cells.
TL;DR: Suramin disrupts mitochondrial function in intact DU145 prostate carcinoma cell monolayers as seen by its causing the release of rhodamine 123 from prestained cells beginning at about 10 microM in 96-well microtiter plates measured with a fluorescent plate scanner, indicating that suramin acts as a respiratory poison or an ionophore.